MOLECULAR INFORMATION
Molecular information
- Type
- Synthetic CNTF-derived peptide · claimed neurogenesis enhancer
P21 is a research-grade CNTF-derived peptide marketed grey-market for nootropic claims.
Claims vs evidence
- Hippocampal neurogenesis — rodent models
- Alzheimer’s-disease relevance — preclinical
- Cognitive benefit in healthy humans — no data
Why we grade it D
Single-source preclinical evidence with no human translation. Grey-market vendors extrapolate beyond the published data.
Frequently asked questions
- What is P21?
- A short peptide derived from ciliary neurotrophic factor (CNTF), originally studied at the New York State Institute for Basic Research as a putative neurogenesis enhancer for Alzheimer's-disease research.
- Is P21 authorised?
- No — preclinical research compound. No human trials are registered.
- Why grade D?
- The mechanism work is from one group. The compound is sold grey-market with nootropic and neurogenesis claims well beyond the rodent preclinical data.